Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease
EM Grischke, A Nusch, N Marschner, W Abenhardt, J Wilke, T Decker, M Just, S Kümmel, C Kurbacher, F Marmé, F Overkamp, F Xuan, M Miller, W Janni · Geburtshilfe und Frauenheilkunde · 2016 · Heft 10
Bibliografische Angaben
Zusammenfassung
Introduction: Ribociclib, a selective, small-molecule inhibitor of CDK4/6, has exhibited antitumor activity as part of doublet or triplet therapy (ribociclib+ET ± PI3K-inhibitor or everolimus) in estrogen receptor-positive breast cancer models, and in the clinical setting. The phase 3, randomized, double-blind, international, MONALEESA-2 study is evaluating the efficacy and safety of ribociclib + letrozole vs. placebo + letrozole in patients with HR+, HER2-negative ABC who have received no prior systemic therapy for advanced disease. Methods: Postmenopausal women (N = 668) with confirmed HR+, HER2-negative ABC w…
